Back to mobile site

Piper Sandler Reiterates Overweight Rating on Lexicon Pharmaceuticals (LXRX)

October 10, 2024 7:40 AM EDT Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $10.00 price target on Lexicon Pharmaceuticals (NASDAQ: LXRX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login